Incident and prevalent cases of ovarian cancer will increase across the seven major markets between 2011 and 2021. In all markets, these increases will be primarily due to the underlying population age structure. This trend is driven by the increase in incident cases among the growing elderly population, as trends among younger age groups will be flat or in very gradual decline.
Features and benefits
- Gain insight into market potential including a robust 10-year epidemiology forecast of ovarian cancer incident and prevalent cases.
- Understand the key epidemiologic risk factors associated with ovarian cancer.
Highlights
Ovarian cancer is the fourth most common cancer among women; it also has the highest mortality. The key risk factors for ovarian cancer are hormone-related; prolonged exposure to free estrogens is believed to stimulate mutations in the epithelial cells of the ovaries.
During the forecast period, incident cases of ovarian cancer will increase across the seven major markets. Datamonitor estimates that 64,700 women were diagnosed with ovarian cancer in the seven major markets in 2011; incident cases will grow by nearly 14% over the forecast period to 73,700 incident cases annually.
During the forecast period, prevalent cases of ovarian cancer will increase across the seven major markets. Datamonitor estimates that 104,800 women were living with ovarian cancer in the seven major markets in 2011; prevalent cases will grow by 10% over the forecast period to 115,400 prevalent cases annually.
Your key questions answered
- What are the most robust sources for ovarian cancer incidence data?
- How will the patient population change over the next decade in the US, Japan, and five major EU markets (France, Germany, Italy, Spain, and the UK)?
- How do changes in population structure and risk factors affect the trend in incident and prevalent ovarian cancer cases?
